TNF Pharmaceuticals (TNFA) Stock Price, News & Analysis

Company Overview

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Key Stats

• Today's Range: $1.13 to $1.26
• 50-Day Range: $1.15 to $1.80
• 52-Week Range: $1.12 to $10.67
• Volume: 64,460 shs
• Average Volume: 27,386 shs
• Market Capitalization: $3.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TNFA Stock Analysis - Frequently Asked Questions

How have TNFA shares performed this year?

TNF Pharmaceuticals' stock was trading at $1.5077 at the beginning of 2024. Since then, TNFA stock has decreased by 19.7% and is now trading at $1.21.
View the best growth stocks for 2024 here.

How do I buy shares of TNF Pharmaceuticals?

Shares of TNFA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of TNF Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TNF Pharmaceuticals investors own include Amprius Technologies (AMPX), Archrock (AROC), Axon Enterprise (AXON), PACCAR (PCAR), Bitfarms (BITF), Bitfarms (BFARF) and BigBear.ai (BBAI).

Company Calendar

• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TNFA
• CUSIP: N/A
• CIK: 1321834
• Web: tnfpharma.com
• Phone: (856) 848-8698
• Fax: 856-848-0269
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,000,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -180.71%
• Return on Assets: -84.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.72
• Quick Ratio: 1.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.21 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 2,760,000
• Free Float: 2,722,000
• Market Cap: $3.34 million
• Optionable: N/A
• Beta: 2.17